Trials / Completed
CompletedNCT01267058
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
Single-blind, Clinical Study of the Immunogenicity and Reactogenicity of SB Biologicals' dTpa, pa Vaccines and a Td Vaccine, Given as a Booster Dose to Healthy Adults, From the Age of 18 Years Onwards
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 550 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to assess the safety and immunogenicity of GlaxoSmithKline Biologicals' (formerly known as SmithKline Beecham Biologicals) combined diphtheria-tetanus-acellular pertussis vaccine in healthy adults, from the age of 18 onwards, in Australia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine | Intramuscular, single dose |
| BIOLOGICAL | GSK Biologicals' acellular pertussis vaccine | Intramuscular, single dose |
| BIOLOGICAL | Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine | Intramuscular, single dose |
Timeline
- Start date
- 1997-09-01
- Primary completion
- 1998-02-01
- Completion
- 1998-02-01
- First posted
- 2010-12-24
- Last updated
- 2010-12-24
Source: ClinicalTrials.gov record NCT01267058. Inclusion in this directory is not an endorsement.